Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide 15 mg) produce significant weight loss (15–21%) and improve obesity-related comorbidities, but discontinuation leads to substantial weight regain, necessitating long-term maintenance therapy.
Use FDA-approved GLP-1 or dual agonists for significant obesity. These drugs work by mimicking gut hormones to reduce appetite and increase satiety. You must take them long-term; stopping leads to weight regain. Discuss titration schedules with your doctor to manage side effects like nausea.
StrongQualifiesVERY_HIGH confidence
Recent pharmacological advancements have substantially transformed obesity management. Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (2.4 mg) and the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide (15 mg) have demonstrated significant weight loss effects (15–21%)... Despite encouraging outcomes, significant challenges remain. Issues such as weight regain after discontinuation... continue to present obstacles.
Why this rating
Based on multiple large-scale Phase 3 RCTs (STEP, SURMOUNT) cited in the review.
Source
Recent advances in the pharmacological treatment of obesity
Ga Eun Nam · Journal of Korean Medical Association · 2025
DOI 10.5124/jkma.25.0058
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →